Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin

被引:50
作者
Kuroda, Junya [1 ]
Kamitsuji, Yuri [1 ,2 ]
Kimura, Shinya [2 ]
Ashihara, Eishi [2 ]
Kawata, Eri [1 ,2 ]
Nakagawa, Yoko [2 ]
Takeuichi, Miki [2 ]
Murotani, Yoshihide [2 ]
Yokota, Asumi [2 ]
Tanaka, Ruriko [2 ]
Andreeff, Michael [3 ]
Taniwaki, Masafumi [1 ]
Maekawa, Taira [2 ]
机构
[1] Kyoto Prefectural Univ Med, Dept Med, Div Hematol & Oncol, Kamigyo Ku, Kyoto 6028566, Japan
[2] Kyoto Univ Hosp, Dept Transfus Med & Cell Therapy, Sakyo Ku, Kyoto 6068507, Japan
[3] Univ Texas Houston, MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Unit 448, Houston, TX 77030 USA
关键词
multiple myeloma; homoharringtonine; apoptosis; Mcl-1; beta-catenin; XIAP;
D O I
10.1007/s12185-008-0081-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since a variety of cell intrinsic and extrinsic molecular abnormalities cooperatively promote tumor formation in multiple myeloma (MM), therapeutic approaches that concomitantly target more than one molecule are increasingly attractive. We herein demonstrate the anti-myeloma effect of a cephalotaxus alkaloid, homoharringtonine (HHT), an inhibitor of protein synthesis, through the induction of apoptosis. HHT significantly reduced Mcl-1, a crucial protein involved in myeloma cell survival, in all three myeloma cell lines examined, whereas certain BH3-only proteins, such as Bim, Bik, and Puma, remained unchanged following HHT treatment, and their expression levels depended on the cell type. HHT also reduced the levels of c-FLIPL/S, activated caspase-8, and induced active truncated-Bid. Thus, HHT-induced apoptosis appears to be mediated via both intrinsic and extrinsic apoptosis pathways, and the resultant imbalance between BH3-only proteins and Mcl-1 may be pivotal for apoptosis by HHT. In addition, HHT treatment resulted in reduced levels of beta-catenin and XIAP proteins, which also contribute to disease progression and resistance to chemotherapy in MM. In combination, HHT enhanced the effects of melphalan, bortezomib, and ABT-737. These results suggest that HHT could constitute an attractive option for MM treatment though its ability to simultaneously target multiple tumor-promoting molecules.
引用
收藏
页码:507 / 515
页数:9
相关论文
共 51 条
[21]   Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets [J].
Hideshima, Teru ;
Mitsiades, Constantine ;
Tonon, Giovanni ;
Richardson, Paul G. ;
Anderson, Kenneth C. .
NATURE REVIEWS CANCER, 2007, 7 (08) :585-598
[22]   Multistep tumorigenesis of multiple myeloma: Its molecular delineation [J].
Iida, S ;
Ueda, R .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (03) :207-212
[23]   A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma [J].
Jagannath, S ;
Barlogie, B ;
Berenson, J ;
Siegel, D ;
Irwin, D ;
Richardson, PG ;
Niesvizky, R ;
Alexanian, R ;
Limentani, SA ;
Alsina, M ;
Adams, J ;
Kauffman, M ;
Esseltine, DL ;
Schenkein, DP ;
Anderson, KC .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (02) :165-172
[24]  
Kantarjian HM, 2001, CANCER-AM CANCER SOC, V92, P1591, DOI 10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO
[25]  
2-U
[26]   The BH3-only protein bid is dispensable for DNA darnage- and replicative stress-induced apoptosis or cell-cycle arrest [J].
Kaufmann, Thomas ;
Tai, Lin ;
Ekert, Paul G. ;
Huang, David C. S. ;
Norris, Fiona ;
Lindemann, Ralph K. ;
Johnstone, Ricky W. ;
Dixit, Vishva M. ;
Strasser, Andreas .
CELL, 2007, 129 (02) :423-433
[27]   Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia [J].
Kuroda, J. ;
Kimura, S. ;
Strasser, A. ;
Andreeff, M. ;
O'Reilly, L. A. ;
Ashihara, E. ;
Kamitsuji, Y. ;
Yokota, A. ;
Kawata, E. ;
Takeuchi, M. ;
Tanaka, R. ;
Tabe, Y. ;
Taniwaki, M. ;
Maekawa, T. .
CELL DEATH AND DIFFERENTIATION, 2007, 14 (09) :1667-1677
[28]   The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate [J].
Kuroda, J ;
Kimura, S ;
Segawa, H ;
Kobayashi, Y ;
Yoshikawa, T ;
Urasaki, Y ;
Ueda, T ;
Enjo, F ;
Tokuda, H ;
Ottmann, OG ;
Maekawa, T .
BLOOD, 2003, 102 (06) :2229-2235
[29]   ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms [J].
Kuroda, Junya ;
Kimura, Shinya ;
Andreeff, Michael ;
Ashihara, Eishi ;
Kamitsuji, Yuri ;
Yokota, Asumi ;
Kawata, Eri ;
Takeuchi, Miki ;
Tanaka, Ruriko ;
Murotani, Yoshihide ;
Matsumoto, Yosuke ;
Tanaka, Hideo ;
Strasser, Andreas ;
Taniwaki, Masafumi ;
Maekawa, Taira .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 140 (02) :181-190
[30]  
Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103